PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

September 6, 2023 by Leave a Comment

Last Updated on September 6, 2023 by

[#item_full_content]

Spread the word

You must log in to post a comment.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Generated by Feedzy

%d bloggers like this:

Reader Interactions